MDxHealth Receives 2011 European Molecular Diagnostics for Oncology Technology Leadership Award
MDxHealth SA announced the receipt of the Frost & Sullivan 2011 European Molecular Diagnostics for Oncology Technology Leadership award. In giving the awards, Frost & Sullivan recognizes the strength and broad applicability of MDxHealth’s epigenetic technology platform in generating advanced tests for cancer assessment and the personalized treatment of patients.
“It is a great honor to receive this award from Frost & Sullivan,” noted Dr. Jan Groen, CEO of MDxHealth. “Our proprietary epigenetic technology, for which we are being recognized, forms the basis of all of our innovative cancer tests. It is good to see the hard work and dedication of all our employees being acknowledged independently.”
In bestowing the award, Frost & Sullivan Senior Research Analyst Cecilia Van Cauwenberghe said: “MDxHealth’s tests help distinguish between different levels of drug responders, while helping to accelerate the pharmaceutical development of a variety of drug therapies and demonstrating higher drug efficacy rates. Such new dynamic work styles enable the companies to overcome regulatory issues expediently, while simultaneously diminishing drug discovery and development costs.”
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Dr. Christie Hunter wins HUPO 2013 Science and Technology Award - AB SCIEX proteomics scientist is recognized for her role in advancing targeted proteomics
Probiodrug Further Expands Scientific Advisory Board by Appointing Prof Dr Dr hc Christian Haass
Anti-tumor protein isolated from ink of a sea slug destroys various kinds of cancers
List_of_papaya_diseases

New 'NanoZymes' use light to kill bacteria - Artificial enzymes could be used in hospitals and toilets
Generex Publishes Results From Pre-Clinical Studies On Immunotherapeutic Vaccine for HPV-Induced Cervical Cancer

New Drug Candidates from Known Compounds - Big data platform for drug repurposing presented
Janssen Pharmaceutica NV and Proteros expand relationship and enter into Global Agreement
Gerhard Schratt, PhD and Professor Albert Sickmann receive the Analytica Research Prize
Elixir Pharmaceuticals and Siena Biotech S.p.A. enter Agreement to Evaluate SIRT1 Inhibitors in Huntington's Disease
GlaxoSmithKline and Genmab seek European Marketing Authorisation of Arzerra (Ofatumab) in Advanced Stage Blood Cancer
